Downsized cell-dervied peptides as potent inhibitors of aS Toxicity
Status / Stage
CompletedDates
1 September 2018 -31 December 2022
Duration (calculated)
04 years 03 monthsFunder(s)
Alzheimer's Research UKFunding Amount
£331,761.17Funder/Grant study page
Alzheimer's Research UKContracted Centre
University of BathPrincipal Investigator
Prof Jody MasonPI Contact
J.Mason@bath.ac.ukPI ORCID
0000-0002-4118-1958WHO Catergories
Understanding risk factorsUnderstanding Underlying Disease
Disease Type
Lewy body dementia (LBD)Parkinson's Dementia
CPEC Review Info
| Reference ID | 228 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Status / Stage | Completed |
|---|---|
| Start Date | 20180901 |
| End Date | 20221231 |
| Duration (calculated) | 04 years 03 months |
| Funder/Grant study page | Alzheimer's Research UK |
| Contracted Centre | University of Bath |
| Funding Amount | £331,761.17 |
Aims
Will investigate the build-up of alpha-synuclein, a key protein implicated in the development of dementia with Lewy bodies and Parkinson’s disease. In this pioneering project, Prof Jody Mason will identify proteins that could effectively stop the build-up of toxic alpha-synuclein and be developed towards future drugs.